Capromorelin

Capromorelin, sold under the brand names Entyce and Elura, is a medication used for the management of weight loss in cats and dogs.^[5][6] Capromorelin is a ghrelin receptor agonist known to increase appetite and weight gain.^[2]

Capromorelin

Clinical data
Trade names	Entyce, Elura, Eluracat
Other names	CP-424,391
License data	US DailyMed: Capromorelin
Routes of administration	By mouth
ATCvet code	QH01AX90 (WHO)
Legal status
Legal status	CA: ℞-only[1] US: ℞-only[2] EU: Rx-only[3]
Pharmacokinetic data
Elimination half-life	2.4 hours[4]
Identifiers
IUPAC name N-[(2R)-1-[(3aR)-2-methyl-3-oxo-3a-(phenylmethyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]-1-oxo-3-(phenylmethoxy)propan-2-yl]-2-amino-2-methylpropanamide
CAS Number	193273-66-4 N
PubChem CID	216208
DrugBank	DB15205 Y
ChemSpider	187411 Y
UNII	0MQ44VUN84
KEGG	D03373
ChEMBL	ChEMBL113313 Y
CompTox Dashboard (EPA)	DTXSID5057886
Chemical and physical data
Formula	C28H35N5O4
Molar mass	505.619 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3=NN(C(=O)[C@@]3(C2)CC4=CC=CC=C4)C)N
InChI InChI=1S/C28H35N5O4/c1-27(2,29)25(35)30-22(18-37-17-21-12-8-5-9-13-21)24(34)33-15-14-23-28(19-33,26(36)32(3)31-23)16-20-10-6-4-7-11-20/h4-13,22H,14-19,29H2,1-3H3,(H,30,35)/t22-,28-/m1/s1 Y Key:KVLLHLWBPNCVNR-SKCUWOTOSA-N Y
NY (what is this?)  (verify)

Capromorelin was developed by Pfizer.^[7][8]

Capromorelin was approved for veterinary use in the United States in May 2016.^[9] It is the second drug approved for the management of weight loss in cats and the first drug approved specifically for the management of weight loss in cats with chronic kidney disease.^[2]

Research

Capromorelin functions to stimulate the secretion of growth hormone and as a ghrelin mimetic which causes the body to secrete human growth hormone in a way usually seen at puberty and in young adulthood. Studies have shown the drug to directly raise insulin growth factor 1 (IGF-1) and growth hormone levels.^[10]

In a one-year treatment trial (starting 1999) with 395 seniors between 65 and 84 years old, patients who received the drug gained an average of 3 lb (1.4 kg) in lean body mass in the first six months and also were better able to walk in a straight line in a test of balance, strength and coordination. After 12 months, patients receiving capromorelin also had an improved ability to climb stairs; however, the results were not good enough to continue the trial for the second planned year.^[11]

As of 2017, capromorelin studies in humans had been discontinued.^[12]

Veterinary uses

Capromorelin is indicated for the management of weight loss in cats and dogs.^[2]